- $3.12m
- $1.24m
- $9.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -355.53% | ||
| Return on Equity | -191.51% | ||
| Operating Margin | -136.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.18 | 11.14 | 10.4 | 9.93 | 9.29 | 12.38 | 14.24 | 16.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iSpecimen Inc. is a technology-driven company. The Company's iSpecimen Marketplace platform is designed to transform the biospecimen procurement process to accelerate medical discovery. The Company's technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. Its iSpecimen Marketplace platform has compiled de-identified healthcare data provided by its healthcare supply partners. The platform is built upon a robust healthcare data set comprised of information about available specimens and research subjects. The Company’s platform helps with administrative and reporting functions for researchers, suppliers, and its internal personnel, including user and compliance management. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data, administrative, compliance and reporting.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 2009
- Public Since
- June 17th, 2021
- No. of Shareholders
- 59
- No. of Employees
- 24
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
NASDAQ Capital Market- Shares in Issue
- 2,496,858
- Address
- 8 Cabot Road, Suite 1800, WOBURN, 08101
- Web
- https://www.ispecimen.com/
- Phone
- +1 7813016700
- Auditors
- WOLF & COMPANY, P.C.
Upcoming Events for ISPC
Similar to ISPC
180 Life Sciences
NASDAQ Capital Market
36Kr Holdings
NASDAQ Capital Market
3 E Network Technology
NASDAQ Capital Market
A2Z Cust2mate Solutions
NASDAQ Capital Market
Abits
NASDAQ Capital Market
FAQ
What is the iSpecimen share price?
As of Today at 15:24 UTC, shares in iSpecimen are trading at $1.25. This share price information is delayed by 15 minutes.
How has the iSpecimen share price performed this year?
Shares in iSpecimen last closed at $1.25 and the price had moved by -76.55% over the past 365 days. In terms of relative price strength the iSpecimen share price has underperformed the S&P500 Index by -78.85% over the past year.
What are the analyst and broker recommendations for iSpecimen?
The overall consensus recommendation for iSpecimen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the iSpecimen dividend yield?
iSpecimen does not currently pay a dividend.
Does iSpecimen pay a dividend?
iSpecimen does not currently pay a dividend.
When does iSpecimen next pay dividends?
iSpecimen does not currently pay a dividend.
How do I buy iSpecimen shares?
To buy shares in iSpecimen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of iSpecimen?
As of the previous close price of $1.25, shares in iSpecimen had a market capitalisation of $3.12m.
Where are iSpecimen shares listed?
Here are the trading details for iSpecimen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ISPC
What kind of share is iSpecimen?
Based on an overall assessment of its quality, value and momentum iSpecimen is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a iSpecimen share price forecast for 2025?
The analyst consensus target price for shares in iSpecimen is $3.00. That is 140% above the last closing price of $1.25.
Analysts covering iSpecimen currently have a consensus Earnings Per Share (EPS) forecast of -$0.79 for the next financial year.
Find out moreWhat is the trend in the iSpecimen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like iSpecimen. Over the past six months, its share price has underperformed the S&P500 Index by -71.07%.
As of the last closing price of $1.25, shares in iSpecimen were trading -63.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the iSpecimen PE Ratio?
The iSpecimen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of iSpecimen?
We do not have data on iSpecimen's directors